Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Leman

Physician Assistant Media, PA Physician Assistant

NPI 1518201466 CMS profile 10931896

1098 W Baltimore Pike, Suite 3402, Media, PA 19063

Open in the dashboard

General payments

$7,909

409 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Leman of Media, PA is reported in the CMS Open Payments database as having received $7,909 across 409 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,470 113
2024 General $1,495 73
2023 General $1,926 105
2022 General $1,424 82
2021 General $595 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Leman
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jennifer Leman were reported at $2,470. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jennifer Leman Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $595 $132 $37–$438 $132
2022 $1,424 $155 $48–$522 $149
2023 $1,926 $167 $52–$557 $160
2024 $1,495 $178 $55–$600 $164
2025 $2,470 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,147 125 payments
  2. Janssen Biotech, Inc. $784 40 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $742 54 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $676 32 payments
  5. Genzyme Corporation $410 15 payments
  6. Celgene Corporation $401 25 payments
  7. Madrigal Pharmaceuticals $387 6 payments
  8. Ardelyx, Inc. $273 13 payments
  9. Ferring Pharmaceuticals Inc. $253 8 payments
  10. Phathom Pharmaceuticals, Inc. $246 11 payments
  11. Other $1,590 80 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,872 407 payments
  2. Education $37 2 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $948 56 payments
  2. XIFAXAN $576 40 payments
  3. ENTYVIO $494 22 payments
  4. STELARA $443 20 payments
  5. SKYRIZI $439 34 payments
  6. TREMFYA $414 21 payments
  7. DUPIXENT $410 15 payments
  8. LINZESS $402 29 payments
  9. ZEPOSIA $401 25 payments
  10. REZDIFFRA $370 5 payments
  11. Other $4,173 227 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

817

Median for Physician Assistant: 241

Drug cost

$101,260

Median for Physician Assistant: $4,110

Branded share of claims

30.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 12 $39,784
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 165 $28,254
Linzess Linaclotide Brand 16 $13,851
Dexlansoprazole Dr Dexlansoprazole Brand 14 $5,124
Lubiprostone Generic 17 $3,695
Lansoprazole Generic 14 $2,033
Famotidine Generic 170 $1,915
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 28 $1,771
Omeprazole Generic 203 $1,464
Pantoprazole Sodium Generic 107 $1,097

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$26,625

Medicare's payments for the services billed

Medicare patients

315

Average age 73

Services billed

369

201 women, 114 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 51%
Ischemic heart disease 32%
Diabetes 31%
Depression 27%
Osteoporosis 23%
Chronic kidney disease 20%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $169
$169 — —
DUPIXENT
  • GENZYME CORPORATION $79
  • Regeneron Healthcare Solutions, Inc. $56
$135 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $125
$125 — —
MAVYRET
  • AbbVie, Inc. $122
$122 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $119
$119 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

409 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record